Oral immunotherapy: The answer to peanut allergy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33526464.
- Also identified by DOI 10.3949/ccjm.88a.20130.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peanut and tree-nut allergies have increased dramatically in prevalence, especially in children. Historically, children with food allergies have been treated through strict avoidance of the allergen. Recently, an oral preparation of peanut allergen (Palforzia) was approved for immunotherapy (ie, desensitization) in children 4 to 17 years old. This article reviews oral immunotherapy and its role in children with peanut allergies.
Medical subject headings
- Nut Hypersensitivity
- Peanut Hypersensitivity